Nutrition and enterocutaneous fistulas

Area of Science:

• Gastroenterology
• Surgical Complications
• Clinical Nutrition

Background:

• Enterocutaneous fistulas (ECFs) present significant management challenges.
• High morbidity and mortality associated with ECFs stem from fluid/electrolyte imbalance, sepsis, and malnutrition.
• Prognostic factors for ECF outcomes are largely established.

Purpose of the Study:

• To review the complex classification and treatment of ECFs.
• To evaluate the role of adjuvant pharmacotherapy in managing high-output ECFs.
• To assess the efficacy of somatostatin and octreotide in ECF treatment.

Main Methods:

• Literature review of ECF classification, prognostic factors, and treatment modalities.
• Analysis of clinical data regarding conservative and surgical management strategies.
• Evaluation of studies utilizing somatostatin and octreotide in conjunction with total parenteral nutrition.

Main Results:

• ECF treatment requires tailored approaches, including surgical or conservative/medical options.
• Nutritional support (enteral or parenteral) is critical and depends on fistula site and patient status.
• Somatostatin (250 microg/d) and octreotide (300-600 microg/d) show promise as adjuvant therapies with total parenteral nutrition for high-output ECFs.

Conclusions:

• Adjuvant somatostatin or octreotide, combined with total parenteral nutrition, can decrease healing time for refractory high-output ECFs.
• These pharmacologic agents may reduce complication rates associated with ECFs.
• Personalized treatment strategies remain essential for optimizing ECF patient outcomes.